K. Papadopoulos

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Pasi A. Jänne, Igor I. Rybkin, Alexander I. Spira et al. · European Journal of Cancer · 2020 · 139 citations

Medicine, Pathology, Cancer Genetics +4

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lillian L. Siu, K. Papadopoulos, Steven R. Alberts et al. · Journal of Clinical Oncology · 2010 · 62 citations

Oral Hedgehog, Pathology, Pathway Antagonist +18

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

Amita Patnaik, Glen J. Weiss, K. Papadopoulos et al. · British Journal of Cancer · 2014 · 47 citations · Full text

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

K. N., Anthony W. Tolcher, Peter P. Lee et al. · Cancer Chemotherapy and Pharmacology · 2012 · 33 citations

Urology, Abiraterone Acetate, Medicine +5

Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Amita Patnaik, Glen J. Weiss, K. Papadopoulos et al. · Journal of Clinical Oncology · 2010 · 30 citations

Sch 900105, Medicine, Hepatobiliary Tumor +10